Acquired haemophilia A: A 2013 update

Thrombosis and Haemostasis

Volumn 110, Issue 6, 2013, Pages 1114-1120

  Franchini, Massimo ^a   Mannucci, Pier Mannuccio ^b  

^a CARLO POMA HOSPITAL   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Acquired haemophilia A; Auto antibodies; Bleeding; FVIII; Inhibitors; Therapy

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; AZATHIOPRINE; BLOOD CLOTTING FACTOR 8; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PHOSPHOLIPID; PREDNISONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RITUXIMAB; VINCRISTINE; VON WILLEBRAND FACTOR;

ALGORITHM; ARTERY THROMBOSIS; BLEEDING DISORDER; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DIFFERENTIAL DIAGNOSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; HEMOPHILIA A; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; META ANALYSIS (TOPIC); NEONATAL HEMORRHAGE; PATHOGENESIS; PLASMA VOLUME; PRIORITY JOURNAL; REVIEW; VEIN THROMBOSIS;

ACQUIRED HAEMOPHILIA A; AUTO-ANTIBODIES; BLEEDING; FVIII; INHIBITORS; THERAPY;

ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; COMORBIDITY; FACTOR VIII; HEMOPHILIA A; HEMOSTATIC TECHNIQUES; HUMANS;

EID: 84888426309     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-05-0363     Document Type: Review

References (94)

1. Cohen AJ, Kessler CM. Acquired inhibitors. Bailleres Clin Haematol 1996; 9: 331-354.
2. Delgado J, et al. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003; 121: 21-35.
3. Franchini M, Lippi G. Acquired haemophilia A. Adv Clin Chem 2011; 54: 71-80.
4. Collins PW, Percy CL. Advances in the understanding of acquired haemophilia A: implications for clinical practice. Br J Haematol 2010; 148: 183-194.
5. Baudo F, et al. Diagnosis and treatment of acquired haemophilia. Haemophilia 2010; 16: 102-106.
6. Coppola A, et al. Acquired inhibitors of coagulation factors: part I-acquired haemophilia A. Semin Thromb Haemost 2012; 38: 433-446.
7. Franchini M, Mannucci PM. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Br J Clin Pharmacol 2011; 72: 553-562.
8. Collins P, et al. Acquired haemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 2007; 109: 1870-1877.
9. Knoebl P, et al. Demographic and clinical data in acquired haemophilia A: results from the European acquired haemophilia (EACH2) registry. J Thromb Haemost 2012; 10: 622-631.
10. Huth-Kuhne A, et al. International recommendations on the diagnosis and treatment of patients with acquired haemophilia A. Haematologica 2009; 94: 566-575.
11. Collins P, et al. Consensus recommendations for the diagnosis and treatment of acquired haemophilia A. BMC Res Notes 2010: 3: 161.
12. Collins P, et al. A population based, unselected, consecutive cohort of patients with acquired haemophilia A. Br J Haematol 2004; 124: 86-90.
13. Franchini M, et al. Acquired haemophilia A: a concise review. Am J Hematol 2005; 80: 55-63.
14. Moraca RJ, Ragni MV. Acquired anti-FVIII inhibitors in children. Haemophilia 2002; 8: 28-32.
15. Franchini M, et al. Acquired haemophilia in pediatrics: a systematic review. Pediatr Blood Cancer 2010; 55: 606-611.
16. Tufano A, et al. Acquired haemophilia a in the elderly: case reports. Curr Gerontol Geriatr Res 2010; 2010: 927503.
17. Solymoss S. Postpartum acquired factor VIII inhibitors: results of a survey. Am J Haematol 1998; 59: 1-4.
18. Baudo F, de Cataldo F. Acquired factor VIII inhibitors in pregnancy: data from the Italian Haemophilia Registry relevant to clinical practice. Br J Obstetr Gynecol 2003; 110: 311-314.
19. Franchini M. Postpartum acquired factor VIII inhibitors. Am J Hematol 2006; 81: 768-773.
20. Tengborn L, et al.; EACH2 registry contributors. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry. Br J Obstet Gynecol 2012; 119: 1529-1537.
21. Franchini M, et al. Laboratory, clinical and therapeutic aspects of acquired haemophilia A. Clin Chim Acta 2008; 395: 14-18.
22. Verbruggen B, et al. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-251.
23. Reding MT. Immunological aspects of inhibitor development. Haemophilia 2006; 12 (Suppl 6): 30-35.
24. Reding MT, et al. Distribution of Th1-and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired haemophilia patients. Thromb Haemost 2002; 88: 568-575.
25. Oldenburg J, et al. Genetic markers in acquired haemophilia. Haemophilia 2010; 16 (Suppl 3): 41-45.
26. Toschi V, Baudo F. Diagnosis, laboratory aspects and management of acquired haemophilia A. Intern Emerg Med 2010; 5: 325-333.
27. Green D, Lechner K. A survey of 215 non-haemophilic patients with inhibitors to Factor VIII. Thromb Haemost 1981; 45: 200-203.
28. Bossi P, et al. Acquired haemophilia due to factor VIII inhibitors in 34 patients. Am J Med 1998; 105: 400-408.
29. Yee TT, et al. A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period. Clin Lab Haematol 2000; 22: 275-278.
30. Tay L, et al. Twelve years of experience of acquired haemophilia A: trials and tribulations in South Australia. Semin Thromb Haemost 2009; 35: 769-777.
31. Hauser I, Lechner K. Solid tumors and factor VIII antibodies. Thromb Haemost 1999; 82: 1005-1007.
32. Sallah S, Wan JY. Inhibitors against factor VIII in patients with cancer. Analysis of 41 patients. Cancer 2001; 91: 1067-1074.
33. Sallah S, et al. Acquired haemophilia in patients with hematologic malignancies. Arch Pathol Lab Med 2000; 124: 730-734.
34. Franchini M, et al. Acquired factor VIII inhibitors in oncohematology: a systematic review. Crit Rev Oncol Hematol 2008; 66: 194-199.
35. Coppola A, et al. Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Haemost 2011; 37: 929-945.
36. Meiklejohn DJ, Watson HG. Acquired haemophilia in association with organspecific autoimmune disease. Haemophilia 2001; 7: 523-525.
37. Trotta F, et al. Long-lasting remission and successful treatment of acquired factor VIII inhibitors using cyclophosfamide in a patient with systemic lupus erythematosus. Rheumatology 1999; 38: 1007-1009.
38. Soriano RM, et al. Acquired haemophilia and rheumatoid arthritis. Br J Rheumatol 1987; 26: 381-383.
39. Vignes S, et al. Acquired haemophilia: a rare complication of Sjögren's syndrome. Clin Exp Rheumatol 1996; 14: 559-560.
40. Sievert R, et al. Graves' disease and autoimmune factor VIII deficiency. Thyroid 1996; 6: 245-247.
41. Sallah S, Wan JY. Inhibitors against factor VIII associated with the use of interferon-alpha and fludarabine. Thromb Haemost 2001; 86: 1119-1121.
42. Regina S, et al. Acquired inhibitor to factor VIII in a patient with Hodgkin's disease following treatment with interferon-alpha. Haemophilia 2001; 7: 526-527.
43. Mauser-Bunschoten EP, et al. Formation of antibodies to factor VIII in patients with haemophilia A who are treated with interferon for chronic hepatitis C. Ann Intern Med 1996; 125: 297-299.
44. Tiplady CW, et al. Acquired haemophilia complicating the remission of a patient with high grade non-Hodgkin's lymphoma treated by fludarabine. Clin Lab Haem 2000; 22: 163-165.
45. Franchini M, et al. Drug-induced anti-factor VIII antibodies: a systematic review. Med Sci Monit 2007; 13: RA55-61.
46. Dentale N, et al. Acquisition of factor VIII inhibitor after acute hepatitis C virus infection. Blood 1997; 90: 3233-3234.
47. Hauser I, et al. Post-partum factor VIII inhibitors: a review of the literature with special reference to the value of steroid and immunosuppressive treatment. Thromb Haemost 1995: 73: 1-5.
48. Michiels JJ. Acquired haemophilia A in women post-partum: clinical manifestations, diagnosis and treatment. Clin Appl Thromb Haemost 2000; 6: 82-86.
49. Santoro RC, Prejanò S. Postpartum-acquired haemophilia A: a description of three cases and literature review. Blood Coagul Fibrinolysis 2009; 20: 461-465.
50. Ries M, et al. Severe intracranial haemorrhage in a newborn infant with transplacental transfer of an acquired factor VIII: C inhibitor. J Pediatr 1995; 127: 649-650.
51. Lottenberg R, et al. Acquired haemophilia: a natural history study of 16 patients with factor VIII inhibitor receiving little or no therapy. Arch Intern Med 1987; 147: 1077-1081.
52. Hay CR, et al. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors Organisation (UKHCDO). Br J Haematol 2006; 133: 591-605.
53. Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood 2008; 112: 250-255.
54. Collins PW. Management of acquired haemophilia A. J Thromb Haemost 2011; 9 (Suppl 1): 226-235.
55. Collins PW. Therapeutic challenges in acquired factor VIII deficiency. Hematology Am Soc Hematol Educ Program 2012; 2012: 369-374.
56. Baudo F, et al. Treatment of acquired factor VIII inhibitor with recombinant activated factor VII: data from the Italian Registry of acquired haemophilia. Haematologica 2004; 89: 759-761.
57. Franchini M, et al. Clinical efficacy of recombinant activated factor VII (rFVIIa) in a patient with acquired haemophilia A with high inhibitor titre. Haematologica 2001; 86: 12.
58. Sallah S. Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia 2004; 10: 169-173.
59. Hay CRM, et al. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicenter study. Thromb Haemost 1997; 78: 3-7.
60. Sumner MJ, et al. Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. Haemophilia 2007; 13: 451-461.
61. Franchini M, Lippi G. Recombinant activated factor VII: Mechanisms of action and current indications. Semin Thromb Haemost 2010; 36: 485-492.
62. Baudo F, et al.; EACH2 registry contributors. Management of bleeding in acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood 2012; 120: 39-46.
63. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2: 1700-1708.
64. Aledort LM. Factor VIII inhibitor bypassing activity (FEIBA)-addressing safety issues. Haemophilia 2008; 14: 39-43.
65. Ehrlich JH, et al. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2001; 8: 83-90.
66. Mudad R, Kane WH. DDAVP in acquired haemophilia A: case report and review of the literature. Am J Hematol 1993; 43: 295-299.
67. Franchini M, Lippi G. The use of desmopressin in acquired haemophilia A: a systematic review. Blood Transfus 2011; 9: 377-382.
68. Morrison AE, et al. Use of porcine factor VIII in the treatment of patients with acquired haemophilia. Blood 1993; 81: 1513-1520.
69. Toschi V. OBI-1, porcine recombinant Factor VIII for the potential treatment of patients with congenital haemophilia A and alloantibodies against human Factor VIII. Curr Opin Mol Ther 2010; 12: 617-625.
70. ClinicalTrials. gov Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Haemophilia A. Available at: Recdombinanthttp://clinicaltrials. gov/ct2/show/NCT01178294?term=acquired+haemophilia+obi-1&rank=1. Last accessed: April 24, 2013.
71. Negrier C, et al. Successful treatment of acquired factor VIII antibody by extracorporeal immunoadsorption. Acta Haematol 1991; 85: 107-110.
72. Jansen M, et al. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol 2001; 112: 91-97.
73. Franchini M, et al. Extracorporeal immunoadsorption for the treatment of coagulation inhibitors. Semin Thromb Haemost 2009; 35: 76-80.
74. Spero JA, et al. Corticosteroid therapy for acquired FVIII: C inhibitors. Br J Haematol 1981; 48: 635-642.
75. Lian EC, et al. Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Ann Intern Med 1989; 110: 774-778.
76. Shaffer LG, Phillips MD. Successful treatment of acquired haemophilia with oral immunosuppressive therapy. Ann Intern Med 1997; 127: 206-209.
77. Green D, et al. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost 1993; 70: 753-757.
78. Bitting RL, et al. The prognosis and treatment of acquired haemophilia: a systematic review and meta-analysis. Blood Coagul Fibrinolysis 2009; 20: 517-523.
79. Collins PW, et al. Immunosuppression for acquired haemophilia A: results of the European Acquired Haemophilia (EACH) registry. Blood 2012; 120: 47-55.
80. Schulman S, et al. Cyclosporine therapy for acquired factor VIII inhibitor in a patient with systemic lupus erythematosus. Thromb Haemost 1996; 76: 344-346.
81. Petrovic M, et al. Cyclosporine treatment of acquired haemophilia due to factor VIII antibodies. Haematologica 2000; 85: 895-896.
82. Pardos-Gea J, et al. Acquired haemophilia A: successful treatment with immunosuppression, methylprednisolone pulses and oral cyclosporin. Thromb Haemost 2006; 95: 735-737.
83. Stasi R, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98: 952-957.
84. Wiestner A, et al. Rituximab in the treatment of acquired factor VIII inhibitor. Blood 2002; 100: 3426-3428.
85. Onitilo A, et al. Rituximab in the treatment of acquired factor VIII inhibitors. Thromb Haemost 2006; 96: 84-87.
86. Field JJ, et al. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy. Haemophilia 2007; 13: 46-50.
87. Franchini M. Rituximab in the treatment of adult acquired haemophilia A: a systematic review. Crit Rev Oncol Hematol 2007; 63: 47-52.
88. Sperr WR, et al. Rituximab for the treatment of acquired antibodies to factor VIII. Haematologica. 2007; 92: 66-72.
89. Aggarwal A, et al. Rituximab for autoimmune haemophilia: a proposed treatment algorithm. Haemophilia 2005; 11: 13-19.
90. Coppola A, et al. Optimising management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol 2010; 150: 515-528.
91. Green D. Suppression of an antibody to factor VIII by a combination of factor VIII and cyclophosphamide. Blood 1971; 37: 381-387.
92. Nemes L, Pitlik E. New protocol for immune tolerance induction in acquired haemophilia. Haematologica 2000; 85: 64-68.
93. Zeitler H, et al. Treatment of acquired haemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept. Blood 2005; 105: 2287-2293.
94. Zeitler H, et al. The relevance of the bleeding severity in the treatment of acquired haemophilia-an update of a single-centre experience with 67 patients. Haemophilia 2010; 16: 95-101.